Open an account

CVRx

CVRX · NASDAQ

$1.39+$0.04 (+2.96%)TodayMarket closed ·
Prev close $1.35

About CVRX

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 223 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

Employees
223
Headquarters
Minneapolis, Minnesota
Listed
Jun 30, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
cvrx.com

CVRX key statistics

Market cap
37.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
781.47K
Volume
295.90K
Open price
$1.36
High today
$1.44
Low today
$1.36
52 Week high
$11.30
52 Week low
$1.26

CVRx (CVRX) at a glance

CVRx (CVRX) last traded at $1.39, with a market cap of 37.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.36 and $1.44. The current price is 2.2% above the day's low and 3.1% below its high.

Volume so far is 295.90K shares, below the average of 781.47K shares a day.

Over the past year CVRx has ranged from $1.26 to $11.30, and now sits 1% of the way up that range.

CVRx met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.53 per share against an estimate of -$0.5348.

The average analyst price target is $4.39, 215.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 7 analystsAvg $4.39
Low
$3.54
Now
$1.39
High
$5.25

CVRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 4.2% on average.

  1. Q3 FY24: reported -$0.57 per share against an estimate of -$0.4779
  2. Q4 FY24: reported -$0.43 per share against an estimate of -$0.3835
  3. Q1 FY25: reported -$0.53 per share against an estimate of -$0.5813
  4. Q2 FY25: reported -$0.57 per share against an estimate of -$0.5304
  5. Q3 FY25: reported -$0.49 per share against an estimate of -$0.5115
  6. Q4 FY25: reported -$0.46 per share against an estimate of -$0.4476
  7. Q1 FY26: reported -$0.50 per share against an estimate of -$0.5144
  8. Q2 FY26: reported -$0.53 per share against an estimate of -$0.5348

CVRX news

  • Press releasePRNewswire

    HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

  • Press releaseGlobe Newswire

    HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

  • Press releasePRNewswire

    HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX

  • Press releasePRNewswire

    Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer

  • Press releasePRNewswire

    HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop

Similar companies

Companies in the same industry as CVRx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.